Not independent
Tenure on this board
11.6 yrs
Also a director at
Engene Therapeutics Inc (ENGN)
Meeting calendar
REPL · Annual meeting · Tuesday, September 15, 2026
Replimune Group Inc
8 nominees · 3 ballot items.
Ratify PwC as auditors; advisory approval of executive compensation; approve amendment to increase authorized common shares from 150,000,000 to 300,000,000.
Market cap
$449M
1Y TSR
+22.6%
Board grade
C
Record date
Jul 21, 2026
Filing
DEF 14A
Filed Jul 28, 2026 · DEF 14A
Proposals
On the ballot3
- 1
Ratification of selection of independent registered public accounting firm
ManagementBoard: FORRatify the Audit Committee’s selection of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending March 31, 2027.
- 2
Non-binding advisory approval of executive compensation (Say on Pay
ManagementBoard: FORAdvisory vote to approve, on a non-binding basis, the compensation of the Company’s named executive officers for fiscal year ended March 31, 2026.
- 3
Approval of amendment to increase authorized common stock
ManagementBoard: FORApprove amendment to the Third Amended and Restated Certificate of Incorporation to increase authorized common stock from 150,000,000 to 300,000,000 shares.
More detail
Management requests shareholder approval to amend the Company’s certificate of incorporation to increase the authorized common shares from 150 million to 300 million (total authorized shares 310 million including preferred). The board argues this provides flexibility for capital raises, strategic transactions, equity compensation grants, and other corporate needs without immediate dilution; notes no current specific plans beyond ordinary-course issuances and at-the-market program; and highlights that approval requires a majority of votes cast and that if approved the board can issue shares without further shareholder approval subject to Nasdaq rules. The board recommends a FOR vote, stating the increase is in the best interests of the company and stockholders to support growth, strategic flexibility, and talent retention.
Director elections
Nominees on the ballot8
Not independent
Tenure on this board
2.3 yrs
Independent
Tenure on this board
1.9 yrs
Also a director at
Uniqure NV (QURE)Stevanato Group Spa (STVN)
Independent
Tenure on this board
9.1 yrs
Also a director at
Black Diamond Therapeutics Inc (BDTX)
Independent
Tenure on this board
1.4 yrs
Also a director at
Dbv Technologies SA (DBVT)
Independent
Tenure on this board
4.7 yrs
Also a director at
Karyopharm Therapeutics Inc (KPTI)Vera Therapeutics Inc (VERA)Bicara Therapeutics Inc (BCAX)
Independent
Tenure on this board
8.8 yrs
Also a director at
Cvrx Inc (CVRX)Imagenebio Inc (IMA)
Independent
Tenure on this board
4.3 yrs
Also a director at
Coya Therapeutics Inc (COYA)
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | BAKER BROS. ADVISORS LP | 13.2% | 11,045,336 | $84M |
| 2 | PRICE T ROWE ASSOCIATES INC /MD/ | 9.5% | 7,971,382 | $61M |
| 3 | RTW INVESTMENTS, LP | 8.8% | 7,356,916 | $56M |
| 4 | SUVRETTA CAPITAL MANAGEMENT, LLC | 5.0% | 4,221,836 | $32M |
| 5 | STATE STREET CORP | 4.5% | 3,782,237 | $29M |
| 6 | BlackRock, Inc. | 3.9% | 3,239,115 | $25M |
| 7 | FCPM III SERVICES B.V. | 3.3% | 2,808,368 | $21M |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | 3.3% | 2,759,120 | $21M |
| 9 | D. E. Shaw Co., Inc.Activist | 2.7% | 2,262,138 | $17M |
| 10 | BlackRock, Inc. | 2.7% | 2,238,678 | $17M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Replimune Group Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Simulations Plus IncSLP
Special meeting·Aug 27, 2026·$371M
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$740M
Kestra Medical Technologies LtdKMTS
Annual meeting·Sep 9, 2026·$1.3B
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$1.5B
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.6B
Prestige Consumer Healthcare IncPBH
Annual meeting·Aug 4, 2026·$2.5B
Reference
Frequently asked questions
- When is the Replimune Group Inc 2026 annual meeting?
- Replimune Group Inc (REPL) holds its 2026 annual shareholder meeting on Tuesday, September 15, 2026.
- What is the record date for the Replimune Group Inc 2026 meeting?
- The record date for the Replimune Group Inc 2026 meeting is Tuesday, July 21, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Replimune Group Inc's 2026 meeting?
- The board is presenting 8 director nominees at the Replimune Group Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Replimune Group Inc 2026 meeting?
- Shareholders will vote on 3 proposals at the Replimune Group Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.